Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
Giacomini P, Valenti F, Allegretti M, Pallocca M, De Nicola F, Ciuffreda L, Fanciulli M, Scalera S, Buglioni S, Melucci E, Casini B, Carosi M, Pescarmona E, Giordani E, Sperati F, Jannitti N, Betti M, Maugeri-Saccà M, Cecere FL, Villani V, Pace A, Appetecchia M, Vici P, Savarese A, Krasniqi E, Ferraresi V, Russillo M, Fabi A, Landi L, Minuti G, Cappuzzo F, Zeuli M, Ciliberto G. Giacomini P, et al. Among authors: maugeri sacca m. J Transl Med. 2023 Oct 16;21(1):725. doi: 10.1186/s12967-023-04595-5. J Transl Med. 2023. PMID: 37845764 Free PMC article.
Translating basic research in cancer patient care.
Maugeri-Saccà M, De Maria R. Maugeri-Saccà M, et al. Ann Ist Super Sanita. 2011;47(1):64-71. doi: 10.4415/ANN_11_01_14. Ann Ist Super Sanita. 2011. PMID: 21430342 Free article. Review.
p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.
Vici P, Sperati F, Maugeri-Saccà M, Melucci E, Di Benedetto A, Di Lauro L, Pizzuti L, Sergi D, Terrenato I, Esposito L, Iannuzzi CA, Pasquale R, Botti C, Fuhrman B, Giordano A, Mottolese M, Barba M. Vici P, et al. Oncotarget. 2014 Nov 15;5(21):10382-92. doi: 10.18632/oncotarget.2060. Oncotarget. 2014. PMID: 25071015 Free PMC article.
The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.
Vici P, Mottolese M, Pizzuti L, Barba M, Sperati F, Terrenato I, Di Benedetto A, Natoli C, Gamucci T, Angelucci D, Ramieri MT, Di Lauro L, Sergi D, Bartucci M, Dattilo R, Pagliuca A, De Maria R, Maugeri-Saccà M. Vici P, et al. Oncotarget. 2014 Oct 30;5(20):9619-25. doi: 10.18632/oncotarget.2449. Oncotarget. 2014. PMID: 25294813 Free PMC article. Clinical Trial.
105 results